1. Home
  2. GEAR vs GYRE Comparison

GEAR vs GYRE Comparison

Compare GEAR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GEAR
  • GYRE
  • Stock Information
  • Founded
  • GEAR 2022
  • GYRE 2002
  • Country
  • GEAR United States
  • GYRE United States
  • Employees
  • GEAR N/A
  • GYRE N/A
  • Industry
  • GEAR
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GEAR
  • GYRE Health Care
  • Exchange
  • GEAR NYSE
  • GYRE Nasdaq
  • Market Cap
  • GEAR 1.1B
  • GYRE 1.3B
  • IPO Year
  • GEAR N/A
  • GYRE N/A
  • Fundamental
  • Price
  • GEAR $19.06
  • GYRE $11.90
  • Analyst Decision
  • GEAR
  • GYRE
  • Analyst Count
  • GEAR 0
  • GYRE 0
  • Target Price
  • GEAR N/A
  • GYRE N/A
  • AVG Volume (30 Days)
  • GEAR 1.0M
  • GYRE 144.2K
  • Earning Date
  • GEAR 02-12-2025
  • GYRE 11-13-2024
  • Dividend Yield
  • GEAR N/A
  • GYRE N/A
  • EPS Growth
  • GEAR N/A
  • GYRE N/A
  • EPS
  • GEAR N/A
  • GYRE N/A
  • Revenue
  • GEAR $1,243,790,000.00
  • GYRE $105,033,000.00
  • Revenue This Year
  • GEAR N/A
  • GYRE $25.32
  • Revenue Next Year
  • GEAR N/A
  • GYRE $12.95
  • P/E Ratio
  • GEAR N/A
  • GYRE N/A
  • Revenue Growth
  • GEAR N/A
  • GYRE N/A
  • 52 Week Low
  • GEAR $18.90
  • GYRE $8.26
  • 52 Week High
  • GEAR $44.72
  • GYRE $30.39
  • Technical
  • Relative Strength Index (RSI)
  • GEAR N/A
  • GYRE 52.33
  • Support Level
  • GEAR N/A
  • GYRE $10.39
  • Resistance Level
  • GEAR N/A
  • GYRE $12.59
  • Average True Range (ATR)
  • GEAR 0.00
  • GYRE 1.07
  • MACD
  • GEAR 0.00
  • GYRE 0.28
  • Stochastic Oscillator
  • GEAR 0.00
  • GYRE 68.77

About GEAR REVELYST INC

Revelyst Inc is a house of iconic consumer product brands serving a diverse range of outdoor enthusiasts across the world. It design, develop, manufacture, source and distribute performance gear and precision technologies for golfers, cyclists, off-road riders, skiers, snowboarders, backyard grillers, hikers, campers, anglers and hunters. It has manufacturing and distribution facilities in the U.S., Canada, Mexico and Puerto Rico along with international customer service, sales and sourcing operations in Asia and Europe. Key revenue is generated from United states.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Share on Social Networks: